MERCK Company Profile

✉ Email this page to a colleague

MERCK has ninety-two approved drugs.

There are twenty-seven US patents protecting MERCK drugs.

There are seven hundred and forty-two patent family members on MERCK drugs in sixty-three countries and one hundred and eighty-one supplementary protection certificates in nineteen countries.

International Patents:	742
US Patents:	27
Tradenames:	77
Ingredients:	70
NDAs:	92
Patent Litigation for MERCK:	See patent lawsuits for MERCK
PTAB Cases with MERCK as patent owner:	See PTAB cases with MERCK as patent owner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940-002	Nov 8, 2017		RX	Yes	Yes	10,603,384	⤷ Sign Up	Y			⤷ Sign Up
Merck	NOROXIN	norfloxacin	TABLET;ORAL	019384-002	Oct 31, 1986		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011		DISCN	Yes	No	7,326,708*PED	⤷ Sign Up			Y	⤷ Sign Up
Merck Sharp Dohme	TEMODAR	temozolomide	POWDER;INTRAVENOUS	022277-001	Feb 27, 2009		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Merck	HUMORSOL	demecarium bromide	SOLUTION/DROPS;OPHTHALMIC	011860-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	VIOXX	rofecoxib	TABLET;ORAL	021042-003	Feb 25, 2000	5,691,374*PED	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	5,514,650*PED	⤷ Sign Up
Merck Sharp Dohme	CLARINEX	desloratadine	SOLUTION;ORAL	021300-001	Sep 1, 2004	7,211,582*PED	⤷ Sign Up
Merck	BLOCADREN	timolol maleate	TABLET;ORAL	018017-004	Approved Prior to Jan 1, 1982	3,655,663	⤷ Sign Up
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001	6,472,373*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Oral Solution	70 mg/75 mL	➤ Subscribe	2007-09-07
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2011-02-28
➤ Subscribe	Injection	18 mg/mL, 16.7 mL vials	➤ Subscribe	2015-11-24
➤ Subscribe	Orally Disintegrating Tablets	2.5 mg and 5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-19
➤ Subscribe	Capsule	40 mg, 80 mg and 125 mg	➤ Subscribe	2008-11-03
➤ Subscribe	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg	➤ Subscribe	2012-11-06
➤ Subscribe	Injection	150 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	For Injection	50 mg/vial and 70 mg/vial	➤ Subscribe	2009-06-26
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Capsules	140 mg and 180 mg	➤ Subscribe	2008-03-24
➤ Subscribe	Delayed-release Tablets	100 mg	➤ Subscribe	2014-06-16
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2006-06-21
➤ Subscribe	Tablets	25 mg, 50 mg and 100 mg	➤ Subscribe	2010-10-18
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-25
➤ Subscribe	Injection	115 mg/vial	➤ Subscribe	2012-01-25
➤ Subscribe	for Oral Suspension	125 mg/Kit	➤ Subscribe	2016-11-23

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2576547	21C1038	France	⤷ Sign Up	PRODUCT NAME: VERICIGUAT ET SES SELS, SOLVATES ET SOLVATES DES SELS; REGISTRATION NO/DATE: EU/1/21/1561 20210720
1429780	SPC/GB12/058	United Kingdom	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
2666774	122020000036	Germany	⤷ Sign Up	PRODUCT NAME: RELEBACTAM, ODER RELEBACTAM IN FORM DES MONOHYDRATES, IMIPENEM UND CILASTATIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1420 20200213
1441735	C300340	Netherlands	⤷ Sign Up	PRODUCT NAME: RALTEGRAVIR OF FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER HET KALIUMZOUT; REGISTRATION NO/DATE: EU/1/07/436/001-002 20071220
1412357	300287	Netherlands	⤷ Sign Up	PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER SITAGLIPTINE FOSFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070323
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.